[
    [
        {
            "time": "",
            "original_text": "复星医药(02196)子公司用于治疗胃癌和乳腺癌新药获国家食药监临床试验注册审评受理",
            "features": {
                "keywords": [
                    "复星医药",
                    "子公司",
                    "胃癌",
                    "乳腺癌",
                    "新药",
                    "临床试验",
                    "国家食药监"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药(02196)子公司用于治疗胃癌和乳腺癌新药获国家食药监临床试验注册审评受理",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2022-11-30",
            "original_text": "[快讯]复星医药71万股限售股11月30日解禁",
            "features": {
                "keywords": [
                    "复星医药",
                    "限售股",
                    "解禁"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "[快讯]复星医药71万股限售股11月30日解禁",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "复星医药：子公司抗癌新药临床试验申请获受理",
            "features": {
                "keywords": [
                    "复星医药",
                    "子公司",
                    "抗癌新药",
                    "临床试验",
                    "申请受理"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药：子公司抗癌新药临床试验申请获受理",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "专家诊股：龙辉国际走势偏弱  复星医药26止损",
            "features": {
                "keywords": [
                    "龙辉国际",
                    "复星医药",
                    "走势偏弱",
                    "止损"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "专家诊股：龙辉国际走势偏弱  复星医药26止损",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报:药店分级意见稿出台,坚守细分景气龙头",
            "features": {
                "keywords": [
                    "医药生物",
                    "行业周报",
                    "药店分级",
                    "意见稿",
                    "细分景气龙头"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业周报:药店分级意见稿出台,坚守细分景气龙头",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]